Second Quarter 2023 U.S. GAAP Financial Highlights (in $ thousands, excl. margin items):
Q2 2023 | Q1 2023 | Q2 2022 | % QoQ | % YoY | ||||||||||||||
Revenue | $ | 129,244 |
| $ | 124,535 |
| $ | 129,571 |
| 3.8 | % | -0.3 | % | |||||
Gross Profit | $ | 52,122 |
| $ | 47,081 |
| $ | 50,848 |
| 10.7 | % | 2.5 | % | |||||
Adj. Gross Profit[1,2] | $ | 52,158 |
| $ | 47,696 |
| $ | 55,118 |
| 9.4 | % | -5.4 | % | |||||
Adj. Gross Margin[1,2] |
| 40.4 | % |
| 38.3 | % |
| 42.5 | % | 210 bps | -220 bps | |||||||
Income (Loss) from Operations | $ | 49 |
| $ | (8,269 | ) | $ | (22,108 | ) | N/A |
| N/A |
| |||||
Adj. EBITDA[1,2] | $ | 20,318 |
| $ | 16,364 |
| $ | 12,029 |
| 24.2 | % | 68.9 | % | |||||
Adj. EBITDA Margin[1,2] |
| 15.7 | % |
| 13.1 | % |
| 9.3 | % | 260 bps | 640 bps | |||||||
Net Income (Loss) | $ | (29,037 | ) | $ | (36,572 | ) | $ | (54,255 | ) | 20.6 | % | 46.5 | % |
[1] Denotes a Non-GAAP measure. See “Non-GAAP Financial Measures” in this press release for more information regarding the Company’s use of non-GAAP financial measures, as well as Table 4 for reconciliation, where applicable. |
[2] Excludes |
“Our second quarter results were solid, as we achieved more than
Vita continued, “We believe our best days are ahead of us. The team is energized, incentivized, and aligned with shareholder interests. As we turn our attention to the next 12 months, the operational leverage created by the steps we have already initiated to reduce corporate SG&A, reduce leverage, enhance cash flow from operations and drive innovation through technology and product/brand development will continue in the second half of 2023. We are excited to re-introduce you to
Top 5 Markets by Revenue in Q2[3]:
Top 5 Markets by Adjusted EBITDA in Q2[3]:
[3] Markets are listed alphabetically |
Operational Highlights
Enhancing scale and optimizing strategic retail network:
Driving cultivation expertise and continued improvements:
Sustained momentum on branding initiatives at retail and product levels:
Capital Markets & Liquidity Highlights
Conference Call and Webcast Details
The Company will host a conference call on
To access the live conference call via telephone, participants must pre-register at https://register.vevent.com/register/BI841d5fbde78c466e8d0f2f1f723fdb1b. After registering, instructions will be shared on how to join the call for those who wish to dial in. A live audio webcast of the call will also be available in the Investor Relations section of the Company's website at https://investors.columbia.care/ or at https://edge.media-server.com/mmc/p/hhco3g37.
A replay of the audio webcast will be available in the Investor Relations section of the Company’s website approximately 2 hours after completion of the call and will be archived for 30 days.
About
Non-GAAP Financial Measures
In this press release,
With respect to non-GAAP financial measures, the Company defines EBITDA as net income (loss) before (i) depreciation and amortization; (ii) income taxes; and (iii) interest expense and debt amortization. Adjusted EBITDA is defined as EBITDA before (i) share-based compensation expense; (ii) goodwill and intangible impairment, (iii) adjustments for acquisition and other non-core costs; (iv) gain on remeasurement of contingent consideration, net, (v) fair value changes on derivative liabilities; and (vi) fair value mark-up for acquired inventory. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue. Adjusted Gross Profit is defined as gross profit before the fair mark-up for acquired inventory. Adjusted Gross Margin is defined as gross margin before the fair mark-up for acquired inventory.
The Company views these non-GAAP financial measures as a means to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to the corresponding GAAP financial measure, may provide a more complete understanding of factors and trends affecting the Company’s business. The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety.
Reconciliations of non-GAAP financial measures to their nearest comparable GAAP measures are included in this press release and a further discussion of some of these items will be contained in our quarterly report on Form 10-Q.
Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute forward-looking information or forward looking statements within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Statements concerning Columbia Care’s objectives, goals, strategies, priorities, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition of the Company are forward-looking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “may”, “will”, “would”, “could”, “should”, “continue”, “plan”, “goal”, “objective”, and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements in this press release include, among others, statements related to: expectations related to growth, cost management and financial numbers including free cash flow; our ability to obtain commercial mortgages on eligible properties; our ability to continue to reduce corporate SG&A, reduce leverage, enhance cash flow from operations and drive innovation through technology and product/brand development; the planned opening of additional Cannabist locations; the exchange of the Company’s 2024 notes for the Company’s 9.5% senior secured notes due
The Company has made assumptions with regard to its ability to execute on initiatives, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. Forward-looking information involves numerous assumptions, including the fact that cannabis remains illegal under federal law; the application of anti-money laundering laws and regulations to the Company; legal, regulatory or political change to the cannabis industry; access to the services of banks; access to public and private capital for the Company; unfavorable publicity or consumer perception of the cannabis industry; expansion into the adult-use markets; the impact of laws, regulations and guidelines; the impact of Section 280E of the Internal Revenue Code; the impact of state laws pertaining to the cannabis industry; the Company’s reliance on key inputs, suppliers and skilled labor; the difficulty of forecasting the Company’s sales; constraints on marketing products; potential cyber-attacks and security breaches; net operating loss and other tax attribute limitations; the impact of changes in tax laws; the volatility of the market price of the common shares of the Company; reliance on management; litigation including existing claims and those which may surface from time to time; future results and financial projections; the impact of global financial conditions and disease outbreaks; projected revenue and expected gross margins, capital allocation, EBITDA break even targets and other financial results; growth of the Company’s operations via expansion; statements relating to the business and future activities of, and developments related to, the Company after the date of this press release, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations and plans; expectations that planned transactions will be completed as previously announced; expectations regarding cultivation and manufacturing capacity; expectations regarding receipt of regulatory approvals; expectations that licenses applied for will be obtained; potential future legalization of adult-use and/or medical cannabis under
Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10-K for the year ended
The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this press release as well as statements regarding the Company’s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. No undue reliance should be placed on forward-looking statements contained in this press release. Such forward-looking statements are made as of the date of this press release.
TABLE 1 - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(in US $ thousands, except share and per share figures, unaudited) | ||||||||||||||||
Three Months Ended | ||||||||||||||||
Revenue | $ | 129,244 |
| $ | 124,535 |
| $ | 129,571 |
| |||||||
Cost of sales |
| (77,122 | ) |
| (77,454 | ) |
| (78,723 | ) | |||||||
Cost of sales related to business combination fair value adjustments to inventory |
| - |
|
| - |
|
| - |
| |||||||
Gross profit |
| 52,122 |
|
| 47,081 |
|
| 50,848 |
| |||||||
Selling, general and administrative expenses |
| (52,073 | ) |
| (55,350 | ) |
| (72,956 | ) | |||||||
Profit / (loss) from operations |
| 49 |
|
| (8,269 | ) |
| (22,108 | ) | |||||||
Other income (expense), net |
| (22,781 | ) |
| (17,614 | ) |
| (13,445 | ) | |||||||
Income tax benefit (expense) |
| (6,305 | ) |
| (10,689 | ) |
| (18,702 | ) | |||||||
Net income (loss) |
| (29,037 | ) |
| (36,572 | ) |
| (54,255 | ) | |||||||
Net income (loss) attributable to non-controlling interests |
| (174 | ) |
| 768 |
|
| (427 | ) | |||||||
Net income (loss) attributable to | $ | (28,863 | ) | $ | (37,340 | ) | $ | (53,828 | ) | |||||||
Weighted average common shares outstanding - basic and diluted |
| 405,782,234 |
|
| 401,438,546 |
|
| 394,023,144 |
| |||||||
Earnings per common share attributable to | $ | (0.07 | ) | $ | (0.09 | ) | $ | (0.14 | ) | |||||||
TABLE 2 - CONDENSED CONSOLIDATED BALANCE SHEET (SELECT ITEMS) | ||||||||||||||||
(in US $ thousands, unaudited) | ||||||||||||||||
Three Months Ended | ||||||||||||||||
Cash | $ | 36,997 |
| $ | 40,159 |
| $ | 48,154 |
| $ | 50,023 |
| ||||
Total current assets |
| 248,555 |
|
| 238,479 |
|
| 237,177 |
|
| 208,515 |
| ||||
Property and equipment, net |
| 328,026 |
|
| 348,581 |
|
| 357,993 |
|
| 370,820 |
| ||||
Right of use assets |
| 207,129 |
|
| 210,751 |
|
| 219,895 |
|
| 259,655 |
| ||||
Total assets |
| 951,990 |
|
| 973,021 |
|
| 994,726 |
|
| 1,371,578 |
| ||||
Total current liabilities |
| 227,471 |
|
| 172,363 |
|
| 203,118 |
|
| 178,015 |
| ||||
Total liabilities |
| 797,194 |
|
| 791,696 |
|
| 787,823 |
|
| 870,701 |
| ||||
Total equity |
| 154,796 |
|
| 181,325 |
|
| 206,903 |
|
| 500,877 |
| ||||
Total liabilities and equity | $ | 951,990 |
| $ | 973,021 |
| $ | 994,726 |
| $ | 1,371,578 |
| ||||
TABLE 3 - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||||||
(in US $ thousands, unaudited) | ||||||||||||||||
Three Months Ended | ||||||||||||||||
Net cash provided by (used in) operating activities | $ | (313 | ) | $ | (3,405 | ) | $ | 5,152 |
| $ | (16,770 | ) | ||||
Net cash provided by (used in) investing activities |
| 237 |
|
| (2,552 | ) |
| (3,369 | ) |
| (14,276 | ) | ||||
Net cash provided by (used in) financing activities | $ | (3,086 | ) | $ | (2,037 | ) | $ | (3,652 | ) | $ | (371 | ) | ||||
TABLE 4 - RECONCILIATION OF US GAAP TO NON-GAAP MEASURES | ||||||||||||||||
(in US $ thousands, unaudited) | ||||||||||||||||
Three Months Ended | ||||||||||||||||
Net income (loss) | $ | (29,037 | ) | $ | (36,572 | ) | $ | (54,255 | ) | |||||||
Income tax (benefit) expense |
| 6,305 |
|
| 10,689 |
|
| 18,702 |
| |||||||
Depreciation and amortization |
| 14,615 |
|
| 15,063 |
|
| 20,058 |
| |||||||
Net interest and debt amortization |
| 13,784 |
|
| 13,671 |
|
| 11,499 |
| |||||||
EBITDA (Non-GAAP) | $ | 5,667 |
| $ | 2,851 |
| $ | (3,996 | ) | |||||||
Share-based compensation | $ | 3,468 |
| $ | 6,515 |
| $ | 7,678 |
| |||||||
| - |
|
| - |
| |||||||||||
Adjustments for other acquisition and non-core costs |
| 11,183 |
|
| 6,968 |
|
| 14,727 |
| |||||||
Gain on remeasurement of contingent consideration, net |
| - |
|
| - |
|
| - |
| |||||||
Fair value changes on derivative liabilities |
| - |
|
| 30 |
|
| (6,380 | ) | |||||||
Fair value mark-up for acquired inventory |
| - |
|
| - |
|
| - |
| |||||||
Adjusted EBITDA (Non-GAAP) | $ | 20,318 |
| $ | 16,364 |
| $ | 12,029 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814521708/en/
Investor Contact
SVP, Capital Markets
ir@col-care.com
Media Contact
SVP, Communications
+1.978.662.2038
media@col-care.com
Source: